Rice Partnership’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $25.1M | Buy |
20,925
+258
| +1% | +$264K | 3.05% | 9 |
|
|
2026
Q1 | $19M | Buy |
20,667
+701
| +4% | +$711K | 2.6% | 11 |
|
|
2025
Q4 | $21.5M | Buy |
19,966
+2,164
| +12% | +$2.07M | 2.9% | 12 |
|
|
2025
Q3 | $13.6M | Sell |
17,802
-812
| -4% | -$604K | 1.93% | 17 |
|
|
2025
Q2 | $14.5M | Sell |
18,614
-143
| -0.8% | -$111K | 2.52% | 13 |
|
|
2025
Q1 | $15.5M | Sell |
18,757
-1,495
| -7% | -$1.24M | 3.18% | 8 |
|
|
2024
Q4 | $15.6M | Sell |
20,252
-3,585
| -15% | -$2.97M | 2.98% | 12 |
|
|
2024
Q3 | $21.1M | Buy |
23,837
+398
| +2% | +$358K | 4.25% | 6 |
|
|
2024
Q2 | $21.2M | Buy |
23,439
+104
| +0.4% | +$83.2K | 4.61% | 6 |
|
|
2024
Q1 | $18.2M | Sell |
23,335
-1,389
| -6% | -$989K | 4.28% | 5 |
|
|
2023
Q4 | $14.4M | Sell |
24,724
-1,160
| -4% | -$677K | 3.76% | 5 |
|
|
2023
Q3 | $13.9M | Sell |
25,884
-4,324
| -14% | -$2.23M | 3.94% | 5 |
|
|
2023
Q2 | $14.2M | Sell |
30,208
-47
| -0.2% | -$19.7K | 3.88% | 5 |
|
|
2023
Q1 | $10.4M | Buy |
30,255
+434
| +1% | +$146K | 3.12% | 6 |
|
|
2022
Q4 | $10.9M | Buy |
29,821
+244
| +0.8% | +$86.5K | 3.44% | 7 |
|
|
2022
Q3 | $9.56M | Buy |
29,577
+4,739
| +19% | +$1.5M | 3.07% | 7 |
|
|
2022
Q2 | $8.05M | Buy |
24,838
+469
| +2% | +$141K | 2.83% | 9 |
|
|
2022
Q1 | $6.98M | Buy |
24,369
+4,170
| +21% | +$1.07M | 2.01% | 17 |
|
|
2021
Q4 | $5.58M | Sell |
20,199
-1,275
| -6% | -$323K | 1.59% | 25 |
|
|
2021
Q3 | $4.96M | Buy |
21,474
+8,189
| +62% | +$2.02M | 1.57% | 25 |
|
|
2021
Q2 | $3.05M | Buy |
13,285
+5,567
| +72% | +$1.12M | 0.96% | 31 |
|
|
2021
Q1 | $1.44M | Buy |
7,718
+6,355
| +466% | +$1.24M | 0.51% | 39 |
|
|
2020
Q4 | $230K | Buy |
+1,363
| New | +$204K | 0.09% | 77 |
|
|
2020
Q3 | – | Sell |
-1,263
| Closed | -$207K | – | 98 |
|
|
2020
Q2 | $207K | Sell |
1,263
-753
| -37% | -$116K | 0.11% | 62 |
|
|
2020
Q1 | $280K | Hold |
2,016
| – | – | 0.19% | 57 |
|
|
2019
Q4 | $265K | Buy |
+2,016
| New | +$234K | 0.14% | 64 |
|
|
2019
Q2 | – | Sell |
-2,232
| Closed | -$290K | – | 105 |
|
|
2019
Q1 | $290K | Sell |
2,232
-99
| -4% | -$12K | 0.21% | 62 |
|
|
2018
Q4 | $270K | Hold |
2,331
| – | – | 0.24% | 58 |
|
|
2018
Q3 | $250K | Buy |
+2,331
| New | +$233K | 0.16% | 68 |
|
Other funds holding LLY
Rice Partnership's LLY Position: Q2 2026 in Review
Rice Partnership increased its Eli Lilly (LLY) stake by 1.2% in Q2 2026, buying an estimated $264K and bringing the position to 20,925 shares worth $25.1M. The position accounts for 3.05% of the portfolio, ranked #9.
Rice Partnership first reported a position in LLY in Q3 2018 and has held it in 29 quarters since. 4,599 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Rice Partnership held 20,925 shares of Eli Lilly worth $25.1M as of Q2 2026.
- Rice Partnership bought 258 Eli Lilly shares in Q2 2026, an estimated $264K.
- Eli Lilly made up 3.05% of Rice Partnership's portfolio in Q2 2026, its #9 holding.
- Rice Partnership first reported a position in Eli Lilly in Q3 2018 and has held it in 29 quarters since.
- 4,599 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Rice Partnership's 13F filing for Q2 2026, filed 29 Jul 2026.